PREVENTion of Clot in Orthopaedic Trauma

Model scores of the 29,894 trials active now.

Model score 12% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (381 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-02-18. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: injurytreatingstagerandomizationcreatinine
  Phrases that lowered it: patients whobloodand safetysafety ofaspirin
• Phase: 3 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 11.5% (lowers risk) · Drug's FDA history
• Primary purpose: prevention (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Blinding: single (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 68096 (raises risk) · Drug's FDA history
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Number of arms: 2 (raises risk) · Design
• Drug's FAERS reports marked serious: 74.7% (lowers risk) · Drug's FDA history
• Disease area, respiratory: Yes (raises risk) · Disease area
• Maximum age: not given (raises risk) · Who can join
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Different Approach to Preventing Thrombosis NCT02774265 · started 2016 · scored riskier than 84% of active trials completed
• Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement NCT03182751 · started 2018 · scored riskier than 90% of active trials completed
• RETIC Trial: Reversal of Trauma Induced Coagulopathy Using Coagulation Factor Concentrates or Fresh Frozen Plasma NCT01545635 · started 2012 · scored riskier than 39% of active trials terminated
• Prevention of Postoperative Bleeding in Subcapital Femoral Fractures NCT02150720 · started 2013 · scored riskier than 55% of active trials completed
• A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery NCT00843492 · started 2008 · scored riskier than 19% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.